• Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

    Source: Nasdaq GlobeNewswire / 16 Aug 2022 07:05:00   America/New_York

    CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET.

    About Fulcrum Therapeutics 
    Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.

    Contacts:

    Investors
    Stephanie Ascher
    Stern Investor Relations, Inc.
    stephanie.ascher@sternir.com
    212-362-1200

    Media
    Dee Smith
    Executive Director, Corporate Communications
    Fulcrum Therapeutics, Inc.
    dsmith@fulcrumtx.com
    202-746-1324


    Primary Logo

Share on,